CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene by Egorova, Tatiana V. et al.
RESOURCE ARTICLE
CRISPR/Cas9-generated mouse model of Duchenne muscular
dystrophy recapitulating a newly identified large 430 kb deletion
in the human DMD gene
Tatiana V. Egorova1,2,*, Evgenia D. Zotova2, Denis A. Reshetov3, Anna V. Polikarpova1,2,
Svetlana G. Vassilieva1,2, Dmitry V. Vlodavets4, Alexey A. Gavrilov5, Sergey V. Ulianov6,7,
Vladimir L. Buchman8 and Alexei V. Deykin9
ABSTRACT
Exon skipping is a promising strategy for Duchenne muscular
dystrophy (DMD) disease-modifying therapy. To make this approach
safe, ensuring that excludingoneormore exonswill restore the reading
frame and that the resulting protein will retain critical functions of the
full-length dystrophin protein is necessary. However, in vivo testing of
the consequences of skipping exons that encode the N-terminal actin-
binding domain (ABD) has been confounded by the absence of a
relevant animal model. We created a mouse model of the disease
recapitulating a novel human mutation, a large de novo deletion of
exons 8-34 of the DMD gene, found in a Russian DMD patient. This
mutation was achieved by deleting exons 8-34 of the X-linked mouse
DmdgeneusingCRISPR/Cas9genomeediting,which led toa reading
frame shift and the absence of functional dystrophin production. Male
mice carrying this deletion display several important signs of muscular
dystrophy, including a gradual age-dependent decrease in muscle
strength, increased creatine kinase, muscle fibrosis and central
nucleation. The degrees of these changes are comparable to those
observed inmdxmice, a standard laboratory model of DMD. This new
model of DMDwill be useful for validating therapies based on skipping
exons that encode the N-terminal ABD and for improving our
understanding of the role of the N-terminal domain and central rod
domain in the biological function of dystrophin. Simultaneous skipping
of exons 6 and 7 should restore the gene reading frame and lead to the
production of a protein that might retain functionality despite the partial
deletion of the ABD.
KEY WORDS: Exon skipping, Muscle degeneration, New deletion,
Genome editing, DMD, Mouse model
INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked recessive
disease affecting approximately 1 in 5000 newborn males (Mendell
andLloyd-Puryear, 2013). The disease is characterized byprogressive
muscle wasting, leading to patients becoming fully dependent on
mobility aids early in life. The average lifespan of DMD patients is 20
years, and the major causes of death are respiratory failure and cardiac
arrest due to weakness of the corresponding groups of muscles
(Passamano et al., 2012). The disease is caused by the absence of the
functional dystrophin protein in muscle cells. Dystrophin is a large
(3685 amino acids in humans), evolutionarily conserved protein. It is
a crucial component of a molecular complex, the main function of
which is to ensure musclemembrane integrity and stability by playing
the role of a ‘molecular spring’, connecting a cytoskeletal network to
the sarcolemma and extracellular matrix. Dystrophin consists of four
functional domains: the N-terminal actin-binding domain (ABD), the
central rod domain containing 24 spectrin-like repeats and four
proline-rich hinges, the cysteine-rich domain, and the C-terminal
domain (Fig. 2B) connecting dystrophin to the membrane
components of the dystrophin-associated glycoprotein complex
(DAGC) and the syntrophin-dystrobrevin subcomplex (Gao and
McNally, 2015; Le Rumeur, 2015). When dystrophin is absent or
aberrant, the sarcolemma anchoring of actomyosin complexes
becomes weaker, which effectively disrupts membrane integrity
during muscle contraction and ultimately leads to myofibre necrosis
and inflammation. Regeneration compensates for the loss of
myofibres until the myoblast pool becomes depleted, which is
associated with muscle degeneration and disease progression (Davies
and Nowak, 2006).
Most cases of DMD are caused by frameshift-generating
deletions of one or more exons of the DMD gene, whereas
mutations that preserve the reading frame are the cause of a milder
form of the disease known as Becker muscular dystrophy (BMD)
(Koenig et al., 1989).
Several therapeutic strategies have been proposed for DMD
treatment: premature stop codon ignoring (Aurino and Nigro, 2006;
Malik et al., 2010); upregulating utrophin, a protein that can
functionally substitute for dystrophin (Guiraud et al., 2015); cell
therapy (Bajek et al., 2015); viral delivery of a shortened form of
dystrophin (Le Guiner et al., 2015); and exon skipping with reading
frame restoration via exclusion of several more exons at the splicing
stage (Niks and Aartsma-Rus, 2017). Following successful clinical
trials, an exon skipping procedure in which exon 51 is skipped has
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Administration (FDA); this intervention can be beneficial for ∼13%
of DMD patients (Young and Pyle, 2016). To test the feasibility
of exon skipping as a therapeutic approach for other genetic
variants of DMD, creating animal models recapitulating the
pathophysiological consequences of the disease-associated human
mutations is necessary. The highly conserved sequence and exon-
intron structure between human and mouse dystrophin-encoding
genes make it possible to accurately reproduce human mutations by
targeted modifications of the mouse genome. More than 50 mouse
models with mutations in the Dmd gene have been produced and
characterized. These models include 11 mouse lines with various
single mutations in the gene and many variants of double or
multiple knockouts (McGreevy et al., 2015). Most of the latter
group is based on the mdx mouse model, which bears a premature
stop codon within exon 23 of the mouse Dmd gene (Sicinski et al.,
1989; McGreevy et al., 2015). However, there is only one model
with an affected N-terminal ABD, encoded by exons 1-7
(McGreevy et al., 2015; Vulin et al., 2015).
Accurate modelling of many genetic variants of human DMD
requires the introduction of large deletions into the mouse Dmd gene.
CRISPR/Cas9 technology is an efficient gene-editing strategy for
genomemodifications, including thegeneration of such largedeletions
(Korablev et al., 2017). These large deletions can be created by
simultaneously introducing two single-guide RNAs (sgRNAs) or
sgRNA-encoding plasmids targeting sequences at the border of the
fragment to be deleted together with a Cas9 enzyme source, i.e. an
expression plasmid, mRNA or the recombinant protein itself, into the
mouse zygote. This technology has been successfully used for the
production of cell lines andmouse strains carrying large deletions. For
example, CRISPR/Cas9 has been used to create: a 65 kb deletion in
embryonic stem (ES) cells and mice zygotes by transfection or
injection of two circular plasmids encoding sgRNAs and the Cas9
protein (Zhang et al., 2015); a 95 kb deletion in one-cell rodent
embryos by co-injection of two sgRNAs with the Cas9 protein (Wang
et al., 2015); and a 1Mb deletion in human cell lines by transfection of
sgRNA and Cas9-encoding plasmids (Essletzbichler et al., 2014).
In this study, we used the injection of two sgRNAs and in vitro-
synthesized Cas9mRNA into mouse single-cell embryos to delete a
430 kb fragment of the dystrophin gene spanning exons 8-34. Using
this approach, we produced a mouse model of a novel genetic
variant of DMD that was recently identified in a Russian patient.
This mouse model represents the largest deletion in the Dmd gene.
RESULTS
Identification of a newmutation in the DMD gene leading to
the development of Duchenne muscular dystrophy
We identified a new mutation in the DMD gene of a male patient
of Russian origin. The patient, now 8 years old, was born after
a normal-term pregnancy in a family with no history of neuromuscular
disorders. He began towalk independently at the age of 13months and
developed normally until the age of 5, when the first manifestations of
musclewasting and fatiguewere observed by the parents. At that time,
his physical examination at the Russian Children’s Neuromuscular
Center revealed no gait disturbances. The patient was actively running
and could squat and rise, jump and hop on one or two legs. He did not
use handrails and moved step by step on stairs when ascending or
descending. No pathological features of the cranial nerves were
observed. However, the patient had a slight stiffness of the ankle
joints, scapular winging, calf pseudohypertrophy, macroglossia and
slight hyperlordosis in his lumbar spine. The use of some Gowers’
manoeuvres when rising from the floor was also observed. The
patient’s muscle tone was decreased, and his muscle strength was
∼4-5 on the Medical Research Council Paralysis Scale. The deep
tendon reflexes were absent. During the 6 min walk test, which was
repeated annually, the boy walked 453 metres in 2016 and 527 metres
in 2017. Nevertheless, an electromyography (EMG) study revealed
myogenic changes. Creatine kinase (CK) was markedly elevated to
20,823 U/l (normal is up to 190 U/l), which is consistent with a
diagnosis of DMD. To confirm the diagnosis, a DNA diagnostic
analysis was performed. A multiplex ligation-dependent probe
amplification (MLPA) assay using genomic DNA from the patient
showed the absence of the product from exon 8 to exon 34,
which suggests a deletion in the DMD gene. To confirm the deletion
and to identify its exact borders, whole-genome sequencing was
performed. An ∼0.3 Mb region spanning exons 8-34 that
corresponded to ∼12% of the DMD coding sequence was deleted
from the patient’s genome. The exact coordinates of the deletion in the
Hg19 assembly were chromosome X (ChrX): 32389015-32717668.
To examine whether the patient’s mother was a carrier of the
mutation in theDMD gene, polymerase chain reactions (PCRs) with
four different primers (listed in Table S1) were performed using
genomic DNA from the patient, the patient’s mother and an
unrelated healthy male (negative control). The primer pair
LbF+LbR was used for amplification of a fragment spanning the
beginning of the deletion, and RbF+RbR was used to amplify the
end of the deletion, a combination of LbF+RbR allowed analysis of
the deletion readthrough. Any PCR product from the primer sets
LbF+LbR and RbF+RbR were expected to be amplified in only the
absence of the deletion (Fig. 1A). In contrast, amplification with
primers LbF+RbR would occur in only the presence of the deletion
(Fig. 1B). The results (Fig. 1C) showed that the patient’s mother had
no deletion, which indicated the de novo acquisition of this
mutation. Sanger sequencing of the corresponding PCR products
confirmed the absence of the deletion in the mother’s genome as
well as its presence in the patient (data not shown).
Primary fibroblasts were sampled from the patient and
transdifferentiated into myoblasts to assess full-length dystrophin
expression, which was not detected using antibodies against the
C-end of the protein (Fig. 1D).
Guide selection for generation of the deletion in the mouse
DMD gene
The CRISPR/Cas9 genome editing technique was employed to
generate a mouse model recapitulating the modification of the DMD
gene manifested in the patient’s genome. Deletion boundaries in the
DMD gene of the patient were located in the 7th and 34th introns.
Therefore, to generate a deletion in the mouse genome, sgRNAs in the
corresponding introns of the mouse Dmd gene were designed. Three
sgRNAs within each of these introns were selected using the
CHOPCHOP online search tool (Montague et al., 2014; Labun
et al., 2016) (Table 1 and Fig. 2A). All selected sgRNAs were
predicted to have no off-target sites with less than three mismatches
and were tested in a series of control experiments (Fig. S1). Each
sgRNA was first tested in vitro on a circular recombinant plasmid
containing a PCR-amplified target fragment from the mouse Dmd
gene. For all selected guides, specific (digestion of the target fragment
and lack of digestion of control fragments) and fairly efficient
linearization of the plasmid DNAwas observed in this test (Fig. S1).
Further ex vivo tests were performed on blastocysts, first for each
sgRNA individually to select the most promising guides, followed by
pairwise testing. The scheme of the testing protocol with sgRNA 31 as
an example is shown in Fig. S1, and the efficiency of cleavage for each
sgRNA is shown in Table 1. A combination of sgRNA 31 for cutting
within intron 7 and sgRNA 30 for cutting within intron 34 was chosen
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for the creation of the model. The efficiency of the target fragment
deletion was estimated in seven experiments, in which 120 total
embryos were injected with sgRNA 30+31 and the Cas9mRNA mix
and cultivated up to the blastocyst stage, followed by PCR and
sequence analysis of their DNA (Fig. S1). Deletions were identified in
43 embryos, which corresponded to∼36%of all the injected embryos.
Fig. 1. Analysis ofPCRproductsamplifiedwithprimers encompassing thedeletion in thepatient’sDMDgene. (A,B) The positions of primerswithin the normal
(A) and mutated (B) genes (not drawn to scale). (C) Agarose gel of fragments amplified from the genomic DNA of the patient, his mother and an unrelated healthy
male (as a negative control). The presenceof an 857 bp product amplifiedwith the LbFandLbRprimers fromgenomicDNAof themother and a healthymale indicates
that the DMD gene is intact at the left border of the patient’s deletion. Similarly, the presence of an 823 bp product amplified with the RbF and RbR primers
indicates that the right border of the patient’s deletion is intact in theseDNAs. In contrast, no amplification productswere obtainedwhen the patient’s genomicDNAwas
amplified with these two pairs of primers. A readthrough product of 815 bp was amplified using the LbF and RbR primers only from the genomic DNA of the patient.
M–100 plus DNA ladder (NL002, Evrogen). (D) Western blot analysis of full-length dystrophin expression in myoblasts transdifferentiated from patient and control
human fibroblasts using antibodies against the dystrophinC-terminus (ab15277). Transdifferentiation successwas verified by staining themuscle cell markers desmin
(ab15200) and MyoD (sc-304). Alpha-actin was used as a loading control. A representative image of three independent experiments is shown.
Fig. 2. GuideRNA positions on the gene. (A) A scheme of themouseDmd gene exons (vertical boxes, not drawn to scale) and positions of sgRNAs selected for
generation of a large deletion encompassing a region between introns 7 and 34. (B-D) Schemes of dystrophin protein domain organization: full-length
dystrophin (B), theoretical shortened dystrophin in which expression is possible in muscle cells of patients with deletion of DMD exons 8-34 (C) and theoretical
shortened dystrophin in which expression is possible in the muscle of patients after additional simultaneous skipping of exons 6 and 7 (D).
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Production of mice with the targeted deletion
A total of 639 embryoswere injectedwith theCas9mRNAand sgRNA
30+31 mix and transplanted into 85 recipient mice in ten independent
experiments. Among 94 newborns, 19 mice with the desired deletion
were found,which corresponded to∼20%of all newborns and 3%of all
transplanted embryos. Deletion borders were identified by direct Sanger
sequencing of the PCR products. Alignment to the theoretical sequence
is shown in Fig. S2. Deletion borders for each guide are shown in
Table 2. Taking the N nucleotide of the NGG PAM site as 0, the
positions of these deletion borders spanned from nucleotide −10 to
nucleotide−1 for sgRNA 30 and from nucleotide−3 to nucleotide +21
for sgRNA 31. In one case, the insertion of four nucleotides into the
cleavage sitewasobserved. In two femalemice (#85and#92),more than
onemodification in the genewas revealed, which could be explained by
either different mutations in twoX chromosomes or genetic mosaicism.
For both sgRNA30 and sgRNA31, three probable off-target sites as
predicted by CHOPCHOP online software (Table 3) were chosen for
experimental assessment. In the genomesof all 19 newbornmice, these
sites did not bear any mutations, as verified by the T7 endonuclease I
(T7EI) test for all samples and direct Sanger sequencing of five random
samples for each off-target site (data not shown).
Analysis of the mouse phenotype
Four female mice carrying the deletion of exons 8-34 in theDmd gene
(#35,#40,#64,#101)were used for theproduction of experimental and
control animal cohorts. The mice were first bred with CBA×C57BL/6
(B6CBAF1) hybrid males, and the resulting F1 females that were
heterozygous for the introducedDmdmutation were further bred with
CBA×C57BL/6 males. The male progeny of this cross that inherited
the Dmd mutation (DMDdel8-34 mice) were used for the analysis of
phenotypical changes caused by the mutation, whereas their male
littermates not bearing the mutations were used as wild-type controls.
The animal weight dynamics were assessed from weaning until week
34 in comparisonwith thewild-typecontrol group.Through the first 12
weeks, DMDdel8-34 mice lagged behind the control mice in weight
gain. These mice then reached the same average mass level as the
control group mice before surpassing them in weight (Fig. 3).
The wire hanging test was employed to assess animal muscle
strength. The tibialis anterior (TA) muscle-specific force, force
deficit after two lengthenings and muscle recovery were also
calculated (Fig. 4). DMDdel8-34 mice and their age-matched wild-
type littermates differed significantly in both maximal hanging time
(P-value=0.002, 0.021, 1.52E−4 and 0.009 for corresponding age
groups in the hanging test, Fig. 4A) and muscle force deficit after
two lengthenings in all age groups except those at 10-12 months
(P-value=0.016, 0.001, 0.008 and 0.052, respectively, Fig. 4C).
Specific force differed significantly between groups at 2-3 months,
7-9 months and 10-12 months (P-value=0.016, 0.08, 0.004,
respectively, Fig. 4B) and did not reach significance at 4-6
months (P-value=0.097, Fig. 4B). The muscle recovery rate was
significantly different for 10- to 12-month-old DMDdel8-34 mice in
comparison with those of wild-type mice (P-value=0.017, Fig. 4D).
Mdx mice and their genetic background strain C57BL/10ScSnJ
mice (B10 in figures) were also subjected to experiments to compare
Table 1. Characteristics of RNA guides selected for injections
sgRNA Intron Sequence (5′-3′; PAM shown in brackets) Coordinates
Efficiency on blastocysts
[positive/injected (n experiments)]
sg31 7 GTGGCAGACTAGTAGTTTG(AGG) ChrX:83491137-83491117 32/57 (3)
sg32 7 GACCAGTCAACACTTCAATG(TGG) ChrX:83579279-83579299 9/9 (1)
sg33 7 GTGACATATCCTTAGGCAGC(AGG) ChrX:83570787-83570807 59/95 (6)
sg30 34 TGATCTGTTGGGTCTTCG(GGG) ChrX:83902153-83902170 10/12 (1)
sg34 34 GTAAAGACTCGGCAGTTAAG(AGG) ChrX:83902977-83901997 29/30 (1)
sg35 34 GCGTAGCAGGGGAGTCATTA(AGG) ChrX:83896473-83896453 9/9 (1)
PAM, protospacer adjacent motif.
Table 2. Deletion borders in mice after simultaneous sgRNA 31 and sgRNA 30 injection
Mouse #
Breakpoint near sg30 PAM
[first nt (last nt) of microhomology]
Breakpoint near sg31 PAM
[first nt (last nt) of microhomology] Microhomology sequence
26, 40, 59, 68, 107, 85, 92 −10 (−7) −3 (0) TTG
AAC
30, 32, 35, 63, 64, 66, 95, 85, 92 −7 (−3) +1 (+4) GGTC
CCAG
28 −8 +4 –
62 −1 (−3)
−9
−2 (−4)
−2
TT
AA
–
73 −5 (−2) +18 (+21) TCT
AGA
84 −6 −3 (contains 4 nt insert) –
85, 92 −7 (−3)
−10 (−7)
+1 (+4)
−3 (0)
GGTC
CCAG
TTG
AAC
101 −15 −3 –
Taking the N nucleotide of the NGG PAM site as 0, positions of breakpoint are marked as +, upstream and −, downstream. In two mice (#85 and #92; bold), more
than one modification in the gene was revealed. nt, nucleotide; PAM, protospacer adjacent motif.
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the effects of two different mutations of the Dmd gene. Similar to
mdxmice, full-length dystrophin was not detected in the muscles of
DMDdel8-34 mutant male mice using an antibody that recognizes the
C-terminal epitope of the protein by immunohistochemistry (Fig. 5)
or western blotting (Fig. 6).
Immunostaining and western blot analyses were performed to
evaluate the DAGC component expression levels in sarcolemma
and whole-muscle lysates. As shown in Fig. 7A, significantly
reduced levels of alpha- and beta-sarcoglycans and lower levels of
syntrophin were detected in the sarcolemma of TA cross-sections
harvested from mutant mice compared with those from the wild-
type control. The total protein levels of alpha-sarcoglycan and
beta-dystroglycan were reduced, whereas those of beta-sarcoglycan
and syntrophin were elevated (Fig. 7B).
Haematoxylin and eosin (H&E) staining was used to observe the
overall histopathology of muscles. Representative images from
12-week-old mice are shown in Fig. 8. Histological analysis
showed myofibre damage and many fibres with centrally located
nuclei, which indicated degeneration and subsequent regeneration.
The identified morphological features of DMDdel8-34 muscles
included prominent myofibre necrosis, the presence of infiltrating
inflammatory cells and fibrotic scars replacing damaged myofibres.
The number of centronucleated fibres in skeletal muscles was
twofold higher than that in diaphragms (70-80% and 30-40%,
respectively). Examination of sections showed that skeletal muscles
(TA and triceps) and the diaphragm had more prominent dystrophic
pathomorphology than the heart.
Analysis of muscle morphology on histological sections of
the TA revealed that the median muscle fibre cross-sectional area
(CSA; 604 µm2) and median minimal Feret diameter (20.7 µm)
were significantly smaller (P-value=1.2E–64 and 1.42E–85,
respectively; Fig. 9B and C) in DMDdel8-34 mice than in wild-
type mice. Central nucleation was detected in 86% of myofibres
from DMDdel8-34 mice in comparison with 4% in those of control
mice (Fig. 8, Fig. 9D).
The CK content in the blood serum of DMDdel8-34 mice was
∼10× higher than that in wild-type mice (P-value=0.001), and this
level was not significantly different from the CK in the blood serum
of mdx mice (P-value=0.445, Fig. 9A).
DISCUSSION
A novel, de novomutation in the DMD gene leading to a frameshift
deletion of exons 8-34 was found in a Russian patient with muscular
dystrophy. According to the theoretical translation of the
corresponding shortened mRNA, the presence of only N-terminal
ABD is possible in the muscle cells of the patient (Fig. 2C). We
produced a new mouse strain replicating this Dmd gene mutation
and demonstrated that male mice carrying this mutation
recapitulated several key features of DMD pathology. Thus, this
mouse strain represents a good model of this type of DMD and can
be beneficial for designing a patient-specific therapy based on exon
skipping. The frequency of mutations that can be treated by
simultaneously skipping exons 6 and 7 was estimated as 3%
(Aartsma-Rus et al., 2009). Our data correlate well with published
statistics, as we identified 18 patients with such mutations in the
Russian DMD registry containing ∼600 patients (Table 4).
Contrary to the viral delivery of shortened forms of dystrophin or
cell therapy, the exon skipping approach requires test models for each
mutation type. Today, only a fewmousemodels are available for such
tests, and none is suitable for modelling exon skipping therapy
affecting ABD domains and flanking regions, i.e. exons 1-7 of the
Dmd gene. Thus far, only one murine model involving mutations in
ABD has been generated, and this model represents a Dmd first exon
duplication. In this case, successful exon skipping can completely
restore the reading frame (Vulin et al., 2015). This model cannot be
used to test for the skipping of ABD-coding exons.
Two clinical cases of deletions in ABD listed in the Leiden
database are completely different, as one patient had severe
symptoms and was described as a DMD patient, whereas the
second patient had BMD (Yang et al., 1994; Basak et al., 2006;
White and den Dunnen, 2006). Moreover, deletion of exon 5 results
in severe DMD symptoms, although without a frameshift (Toh
et al., 2016). Deletion of exons 3-9 was shown to be asymptomatic
or lead to the BMD phenotype in 11 of 15 patients (Nakamura et al.,
2016). Four cases of in-frame deletions containing exons 6 and 7
Table 3. Potential off-target site sequences
OT
gene
OT site sequence (5′-3′; PAM
shown in brackets) Chr
Position
within
gene Strand
SgRNA 30: TGATCTGTTGGGTCTTCG
Grid2 TaATCTGTTGGGTCTcCG(GGG) 6 Intron 3 –
Skint5 TtATCTGTTGGGTCTcCG(GGG) 4 Intron 40 –
Sugp2 TttTCTGaTGGGTCTTCG(GGG) 8 Intron 2 +
SgRNA 31: GTGGCAGACTAGTAGTTTG
Tff3 cTGcCAGACTAcTAGTTTG(GGG) 17 Intron 1 –
Unc5c cTGGCAGACTAaTAGcTTG(AGG) 3 Intron 1 +
Fmn2 tTGGaAtACTAGTAGTTTG(TGG) 1 Intron 1 +
Lowercase indicates nucleotides that differ from those in the guide RNA
sequence. Chr, chromosome; OT, off-target; PAM, protospacer adjacent motif.
Fig. 3. Effect of the introduced mutation
on body weight gain. DMDdel8-34 mice
(blue) and their control CBA×C57BL/6
(red) male littermate mice were regularly
weighed from the age of 5 weeks to 33
weeks of age. Each data point is the mean
±2 s.e.m. (n=21-93; *P<0.05, **P<0.01,
one-way ANOVA).
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listed in the Universal Mutation Database (UMD)-DMD database
(6-10, 6-12 and 6-13 exons) are characterized as DMD or
intermediate muscular dystrophy (Béroud et al., 2000). Based on
these conflicting data, we cannot conclude that the skipping of
exons 6 and 7 is a suitable treatment strategy for patients with
mutations similar to that described in our manuscript.
In the case of successful skipping of exons 6 and 7, mRNA
translation will result in a short dystrophin protein that lacks part of
the ABD (CH2) and part of the rod domain, including hinges 1-2
and spectrin repeats 1-12, but will contain repeats 16 and 17, which
represent the nNOS-binding site, cysteine-rich domain and
C-terminal domain (Allen et al., 2016); a schematic of the
resulting protein is shown in Fig. 2D. Thus, further experiments
should explain the roles of absent domains in dystrophin function
and possible enhancements of DMD treatment strategies.
Our new mouse model of DMD shows the main biochemical and
histological symptoms of dystrophy, such as increased CK content
and number of centralized nuclei, and decreased average minimal
Feret diameter and myofibre CSA. In addition, extensive
calcification, fibrosis, immune cell infiltration and reduced levels
of DAGC components on the sarcolemma were detected. All of the
symptoms were similar to those of mdx mice of the same age.
Dystrophin deficiency and its consequences influence the locomotor
activity of model mice. Lowered muscle strength and endurance,
force deficit and longer recovery time were shown for different age
groups of model animals in comparison with those of their age-
matched wild-type littermates. The weight dynamics of mutant mice
differed from those of control mice and were similar to those of mdx
mice. The DMDdel8-34 mouse body weight was lower in postnatal
development but reached that of the wild-type level at 9-10 weeks
of age, and the mutant mice then outgrew their counterparts. In
addition, a higher diversity in body weight was characteristic of the
mutant mice. Similar dynamics have been shown for mdx mice, as
they were shown to gain body weight comparably to wild-type mice
by 11 weeks of age (Durrant et al., 2012).
The mouse model described herein represents the largest deletion
of the Dmd gene created in animals using the CRISPR/Cas9 tool
(Wells, 2018). The CRISPR/Cas9 genome editing strategy is of
major interest as a potent tool for the creation of new models
and gene recovery to cure various pathogenic conditions. Two
mechanisms of double-strand break repair exists in cells, homology-
directed repair (HDR) and non-homologous end-joining (NHEJ).
Deletion borders in the analyzed mutant mice indicate NHEJ
participation in double-strand break reparation after Streptococcus
Fig. 4. Muscle force examinations. (A) Performances of DMDdel8-34 and wild-type control mice in the wire hanging test. Animals were tested at the indicated
ages. Each session lasted 300 s, and mice were subjected to three trials. (B) Specific force comparison of DMDdel8-34 and wild-type control mice. The TA
contraction force was normalized to the muscle cross-sectional area. (C) Force deficit comparison of DMDdel8-34 and wild-type control mice. The contraction force
drop-off was assessed 1 min after the second muscle lengthening. (D) Performance of DMDdel8-34 and wild-type control mice in the muscle recovery test.
The recovery rate was assessed 15 min after the second muscle lengthening. The heavy black line inside each box marks the median of that distribution. The
lower and upper box boundaries mark the 25th and 75th percentiles of each distribution, respectively. Whiskers represent 95% confidence intervals. Outliers
are identified with a filled circle. Age groups were analyzed in pairs using the Mann–Whitney U-test for nonparametric data, *P<0.05, **P<0.01, n=6.
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pyogenes Cas9 mRNA/gRNA injection into zygotes. Moreover,
two types of microhomology sequences were identified in a
majority of samples (14 of 19, Table 2). These data correlate with
data published for Arabidopsis thaliana (Shen et al., 2017) and
tracheal epithelial (CFTE) mammalian cell line experiments
(Hollywood et al., 2016). For different applications, predicting the
exact deletion borders after the simultaneous injection of two guide
RNAs in complex with Cas9 can be important. The results reported
herein suggest that assuming all known data from in vivo Cas9
experiments can help to make such a prediction.
The spatial organization of the genome has recently gained
substantial attention as a factor that influences the patterns of
chromosomal rearrangements and translocations (Fudenberg et al.,
2011; Zhang et al., 2012). By exploring publicly available long-
range chromatin interaction (Hi-C) data [3D Genome browser:
visualize Hi-C, ChIA-PET, Capture Hi-C data; http://promoter.bx.
psu.edu/hi-c/ (accessed: 21 November 2017)] for the 1Mb region of
ChrX encompassing the deletion, we found that in several human
cell lines, including mesenchymal and neural stem cells,
chromosomal sites flanking the deletion preferred to interact with
each other (Fig. 10). It thus may be hypothesized that the location of
the two sites in spatial proximity may predispose them to deletion.
Future research may help to elucidate the molecular mechanisms
that underlie the formation of the deletion.
MATERIALS AND METHODS
Ethics statement
All animal studies were conducted according to experimental practices and
standards approved by the Ethics Committee of the Institute of Gene
Biology, Russian Academy of Sciences. All mice were maintained under a
controlled photoperiod (lights on 07:00-19:00). Food and water were
provided ad libitum.
Patient
The patient was identified and enrolled at the Russian Children’s
Neuromuscular Center in Moscow, Russia. Two family members, the
8-year-old boy who presented with the symptoms of DMD and his mother,
took part in the study. Informed consent was obtained from the participants.
The diagnosis of DMD was made on the basis of symptoms, EMG data and
blood CK levels and was confirmed by the MLPA genetic assay.
Cell lines
Cell lines used in this work were recently authenticated using short tandem
repeat DNA profiling (Gordiz) and tested for contamination using PCR.
Fibroblast transdifferentiation into myoblast
Lentivirus production and transdifferentiation experiments were performed
based on protocols described by Kabadi and colleagues (Kabadi et al.,
2015). Briefly, 0.5 million HEK293T cells were plated per six-well plate.
The following day, cells were transfected with 1 μg of transfer vector
(LV-TRE-VP64 human MyoD-T2A-dsRedExpress2, a gift from Charles
Gersbach, Addgene plasmid #60629), 0.3 μg of pMD2G (Addgene plasmid
#12259) and 0.5 μg of psPAX2 (Addgene plasmid #12260) using linear
polyethylenimine transfection reagent; the media was changed 12-14 h
post-transfection. At 48 h after the media change, the viral supernatant was
Fig. 5. Deletion of exons 8-34 in the dystrophin gene
results in the absence of dystrophin protein in the
sarcolemma of muscle cells. Cross-sections through the
TA muscle of mdx and DMDdel8-34 mutant male mice, as well
as those of their respective wild-type control C57BL/10ScSnJ
(B10) and CBA×C57BL/6 mice, were immunostained with an
antibody against the C-terminal amino acids of dystrophin
(ab15227) and an Alexa Fluor 488 secondary antibody
(green channel). The absence of dystrophin is evident in both
DMDdel8-34 and mdx mutant mice. Scale bars: 75 µm.
Fig. 6. Deletion of exons 8-34 of the Dmd gene results in the absence
of the full-length dystrophin protein from the muscles of male mutant
mice.Western blot analysis of protein lysates from muscles of DMDdel8-34 and
mdx mutant male mice, as well as those of their respective wild-type control
C57BL/10ScSnJ (B10) and CBA×C57BL/6 mice, using an antibody against
the dystrophin protein (ab154168). Equal loading of protein lysates was
confirmed by reprobing the membrane with an antibody against alpha-actin.
The absence of full-length dystrophin is evident in muscle lysates of both
DMDdel8-34 and mdx mutant mice.
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pooled and passed through a 0.45 μm filter. Primary fibroblasts from
the patient and healthy male control were transduced with a MyoD-
encoding lentivirus in the presence of 4 μg/ml polybrene. Cells were
selected in 2 μg/ml puromycin to obtain a pure population of transduced
cells. Cells were expanded in standard growth medium supplemented with
puromycin. Selected cells were grown to confluence, and MyoD transgene
expression was induced by supplementing the medium with 3 μg/ml
doxycycline. Cells were given fresh media supplemented with doxycycline
every 2 days. Samples were collected for analysis after 14 days of
doxycycline induction.
Mutation analysis
Total genomic DNA was extracted from the patient’s venous blood using
the QIAamp DNA mini kit (Qiagen). The MLPA analysis was performed
using the SALSA MLPA probe mixes P034 DMD-1 and P035 DMD-2
(MRC-Holland). For library preparation, 1 µg of DNA was fragmented
using a Covaris S220 instrument. End repair, adenylation, adapter ligation
and PCR amplification were performed using reagents from the TruSeq
DNA sample preparation kit (Illumina) according to the manufacturer’s
instructions. The library was quantified using qPCR primers I-qPCR-1.1
(5′-AATGATACGGCGACCACCGAGAT-3′) and I-qPCR-2.1 (5′-CAA-
GCAGAAGACGGCATACGA-3′) diluted to 10 pM and sequenced on a
HiSeq2000 instrument (three lanes of v.3 flowcell; Illumina) with a read
length equal to 101 from each end of the fragment. FASTQ files were
generated using CASAVA-1.8.2 (Illumina), and 52.5 Gb of total raw data
were obtained. Genomic analysis was performed using the Science Advice-
pipeline (Research Center for Genetic Medicine, Science-Advice.com).
To study whether the patient’s mutation was inherited from his mother, a
set of four PCR primers were designed. The first pair of primers, LbF and
LbR, were designed to amplify an 857 bp fragment overlapping the left
border of the deletion in the patient’s genome, and the second pair, RbF and
RbR, were designed to amplify an 823 bp fragment overlapping its right
border. For these two primer pairs, amplification is observable only in the
absence of the deletion. The combination of the LbF and RbR primers
yielded a readthrough product of 815 bp in the case of deletion, and no
amplification product could be generated from the normal allele because of
the distance between these primers (∼0.3 Mb). The PCR amplification
programmewas as follows: an initial denaturation step for 5 min at 94°C; 30
cycles of 30 s at 94°C, 30 s at 58°C and 1 min at 72°C; and a final step of
7 min at 72°C. PCRwas performed using the GenePak PCR core kit (Izogen
Fig. 7. Analysis of DAGC component expression levels in the muscles of DMDdel8-34 mice in comparison with that in wild-type controls. (A) Cross-
sections through the TA muscle of DMDdel8-34 mutant male mice, as well as those of their wild-type control CBA×C57BL/6 mice, were immunostained with
an antibody against DAGC proteins (green). Nuclei were counterstained with To-Pro-3 Iodide (pseudocoloured magenta). Scale bars: 100 µm. (B) Total
muscle lysates of TA muscles from DMDdel8-34 and CBA×C57BL/6 mice were analyzed by western blot using an antibody against DAGC proteins. Alpha-actin
was used as a loading control. Representative images of three independent experiments are shown. Graphical representation of DAGC component expression
in TA muscle of DMDdel8-34 in comparison with that in wild-type control mice from blots is shown to the right. Downregulation of alpha-sarcoglycan and
beta-dystroglycan, but upregulation of beta-sarcoglycan and syntrophin total protein level are shown. Bar charts show the mean±2 s.e.m.
8
RESOURCE ARTICLE Disease Models & Mechanisms (2019) 12, dmm037655. doi:10.1242/dmm.037655
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Lab Ltd, Russia). The electrophoretic detection of PCR products was
performed using a 2% agarose gel with an intercalating dye. The direct
sequencing of PCR-amplified products was performed at Evrogen.
Cas9mRNA in vitro transcription
The Cas9 expression construct pET28a/Cas9-Cys, a gift from Hyongbum
Kim (Addgene plasmid #53261), was linearized and transcribed in vitro
using the mMessage mMachine T7 kit (Ambion) followed by phenol-
chloroform extraction.
sgRNA design and synthesis
sgRNAs were selected using CHOPCHOP online software (Montague
et al., 2014; Labun et al., 2016) in the 7th and 34th introns of the mouse
Dmd gene (Dmd GenBank ID: NC_000086.7). For sgRNA synthesis, two
partially complementary oligonucleotides (oligos) were used: sgR, encoding
the T7 promoter, and sgF, encoding the guide RNA sequence. Both oligos
were synthesized by Evrogen. For template amplification, oligos were
combined in an equimolar ratio and polymerized in a T100 thermocycler
(Bio-Rad) using the following programme: 95°C for 1 min; 30 cycles of 95°C
for 30 s, 65°C for 30 s and 72°C for 30 s; and 72°C for 5 min. The GenePak
PCR core kit was used (Izogen Lab). To purify the template from the reaction
mix, the Clean Up kit (Evrogen) was used, and the sgRNA was then
transcribed from the T7 promoter in vitro using the RiboMAX Express kit
(Promega). Reaction components were removed by phenol-chloroform
extraction followed by isopropanol precipitation. Synthesized sgRNAs were
dissolved in nuclease-free water. The concentration was determined using the
Qubit RNA HS kit (Thermo Fisher Scientific), and the sgRNAs were stored at
−70°C before use.
We also used the SureGuide Cas9 programmable nuclease kit (Agilent) to
test freshly synthesized sgRNA activity in vitro. As a template for the new
guide, a target region containing plasmid DNAwas used. The target region
for each guide was amplified and ligated into vector pTZ57R/T using
an InstaClone PCR cloning kit (Thermo Fisher Scientific).
Microinjections into the pronucleus of zygotes, embryo
cultivation and transfer
In immature female mice (C57BL/6×CBA) weighing 12-13 g, superovulation
was induced by administrating 5 units of pregnant mare serum gonadotropin
(Folligon, Intervet International) and 5 units of human chorionic gonadotropin
(hCG, Pregnil, N.V. Organon) 46-48 h later. After injection, the femalemouse
was immediately placed in a cage with a male mouse for mating. Ovulation
occurred within 11-14 h after hCG injection. Fertilized eggs were surgically
washed out within 12-13 h after copulation, i.e. 25-27 h after hCG injection.
The two pronuclear-stage zygotes were placed in a chamber consisting of two
coverslips with one fixed above the other such that the upper and lower droplet
edges of the M2 medium (MTI-GlobalStem) were flat and parallel. Pronuclei
were visualized using a differential interference contrast microscope (Axiovert
200, Carl Zeiss). The microinjection needles were made from G100 glass
capillaries (Narishige) on a P97 puller (Shutter Instruments) and holder
capillaries were made from GD1 capillaries (Narishige) on a PC-10 puller
(Narishige) and MF-900 Microforge (Narishige). For microinjection, guide
RNA (20 ng/µl) was mixed withCas9mRNA (50 ng/µl) or Cas9 protein (0.1
pM; New England Biolabs) in TE buffer [10 mMTris-HCl (pH 7.4); 0.1 mM
EDTA]. The components were mixed immediately before microinjection and
incubated for 5 min at 37°C. The resulting genome-editing complex was
microinjected into the male pronucleus of mouse zygotes. After
microinjection, the zygotes were cultured for 2-3 h in a CO2 incubator (150
IGO, Thermo Electron Corporation) at 5% CO2 and 100% humidity and then
assessed visually; those that were in satisfactory condition were transferred to
recipient mice or left for 3 days in KSOM buffer (MTI-GlobalStem) to form a
blastocyst. Cultivation took place in Petri dishes (35 mm in diameter) in
50-60 μl droplets; the top of the droplets was coveredwith embryo-tested light
mineral oil (Merck KGaA). All the preparatory procedures were performed in
a laminar flow hood.
Total blastocyst DNA preparation and PCR amplification of the
target fragment
Under a microscope, each embryo in 1 µl of buffer was sequentially
transferred through three drops of PCR-quality water (Evrogen) using an
automatic pipette and filtered tips, and placed in a 1 μl volume drop on the
wall of a 0.2 ml tube; 1 μl of water from the last drop was used as the PCR
negative control. When necessary, samples at this stage were frozen until
further analysis and stored at −20°C. Blastocysts were lysed via proteinase
K processing with detergent using the Sakurai et al. technique (Sakurai
et al., 2008) with modifications. Briefly, 20 μl of buffer [proteinase K
(125 μl/ml), Tris-HCl (100 mM, pH 8.3), KCl (100 mM), gelatine 0.02%
and Tween-20 0.45%] was added to the test tubes for lysis. The tubes were
incubated for 10 min at 56°C and then for 10 min at 95°C to inactivate
proteinase. PCR analysis was performed immediately after sample
preparation. The target region around the sgRNA recognition site was
amplified using pairs of the forward and reverse primers sg30-sg35 (listed in
Table S1) corresponding to the tested sgRNA. The GenePak PCR core kit
(Izogen Lab) was used for PCR. The amplification programmewas as
follows: 95°C for 1 min; 40 cycles of 95°C for 30 s, 60°C for 30 s
and 72°C for 30 s; 72°C for 5 min.
Mutational analysis using bacteriophage T7 endonuclease I
PCR amplicons of target genomic regions were mixed with control non-
mutated product, denatured and annealed at a temperature gradient from 95
to 25°C at a speed of 0.1°C/s. Hybridization products were digested using
the T7EI enzyme (New England Biolabs) for 1 h at 37°C. Reaction products
Fig. 8. Representative images of H&E-stained muscles. Muscle fibres of
control CBA×C57BL/6 mice had equal diameter; the nuclei are located on the
periphery of muscle fibres. DMDdel8-34 mice had variation in fibre size; over half
of the myofibres had centrally located nuclei. H&E staining also revealed signs
of inflammation, necrosis and regeneration in the skeletal muscles and
diaphragmof DMDdel8-34mice. Thewhite arrowhead indicates the regeneration
zone (small myofibres with a more basophilic cytoplasm); the black
arrowheads indicate infiltrating inflammatory cells. Scale bars: 100 µm.
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were separated by electrophoresis in an ethidium bromide-stained 2%
agarose gel. The deletion boundaries and insertion sizes were determined by
Sanger sequencing of the PCR products (Genome Center). The PCR primers
used are listed in Table S1.
Deletion detection on blastocysts
For deletion detection, a forward primer for the seventh intron (sg31F)
and a reverse primer for the 34th intron (sg30R) were used, and a
700 bp product was amplified in only the case of a deletion. Control
primers for the TET1 gene were used to verify the presence of
DNA in the samples (primers are listed in Table S1). The GenePak
PCR core kit (Izogen Lab) was used for PCR. The amplification
programme was as follows: 95°C for 1 min; 40 cycles of 95°C for 30 s,
60°C for 30 s and 72°C for 30 s; 72°C for 5 min. Reaction products
were separated by electrophoresis in an ethidium bromide-stained 2%
agarose gel.
Mouse genotyping
For mouse genotyping, tail biopsies were collected at the age of 2 weeks. A
crude DNA sample was prepared using brief alkaline lysis; a small tail
biopsy fragment was lysed in an alkaline lysis buffer [25 mM NaOH,
0.2 mMNa2-EDTA (pH 12)] for 1 h at 95°C, neutralized with 40 mM Tris-
HCl (pH 5) and 2 μl of the resulting solution was used as a template for
PCR. The primers, programme and detection methods were the same as
those used for blastocysts.
Off-target assay
Potential off-target sites of the sgRNAs were predicted using the E-CRISP
online tool (Heigwer et al., 2014). The top three sites with off-target
mutations were selected and used for PCR, T7EI and sequence analysis
(Table 3). Geneious 8.1.3 (www.geneious.com) was used for sequence
analysis. The primers used are shown in Table S1.
Fig. 9. Histological and biochemical changes in the muscles of DMDdel8-34 mutant mice. (A) CK was measured in the blood sera of 12-week-old DMDdel8-34
and mdx mutant male mice, as well as in that of their respective wild-type control C57BL/10ScSnJ (B10) and CBA×C57BL/6 male mice. (B-D) The myofibre
cross-sectional area (B), minimal Feret diameter (C) and percent of myofibres with centralized nuclei (D) were analyzed in the cross-sections through the TA
muscles of 12-week-old DMDdel8-34 andmdxmutant malemice, as well as in those of their respectivewild-type control C57BL/10ScSnJ (B10) and CBA×C57BL/6
mice male mice. The heavy black line inside each box (A,C,D) marks the median of that distribution. The lower and upper box boundaries mark the 25th and
75th percentiles of each distribution, respectively. Whiskers represent 95% confidence intervals. Outliers are identified with a filled circle. Groups were
compared in pairs using the Mann–Whitney U-test for nonparametric data. **P<0.01, n=6 (A); n=800 per group (C,D). Bar chart (B) shows the mean±2 s.e.m. of
measured parameters. **P<0.01, using one-way ANOVA with Fisher’s LSD post hoc test. n=800 per group.
Table 4. Russian DMD patients considered for potential exons 6 and 7
skipping approach
Patient # Deleted exons in DMD gene Phenotype
1 8-38 DMD
2 8-9 DMD
3 8-41 DMD
4 8-9 DMD
5 8-41 DMD
6 8-9 DMD
7 8-30 DMD
8 8-47 DMD
9 8-29 DMD
10 8-18 DMD
11 8-12 DMD
12 8 DMD
13 8-41 DMD
14 8-44 DMD
15 8-16 DMD
16 8 DMD
17 8 DMD
18 8-34 DMD
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Sample collection
Mice were euthanized by avertin overdose at the age of 12 weeks.
Blood samples were collected from the heart with an insulin syringe
and 30 G needle. Muscle samples were collected and either immediately
frozen in liquid nitrogen for total protein extraction and western blot
analysis or immobilized on Tissue-Tek O.C.T. Compound (Sakura
Finetek) and frozen in liquid nitrogen-cooled isopentane for
immunohistochemistry.
Histological analysis of myofibres
Frozen 5 µm cross-cryosections of mouse TA muscles were fixed in
4% paraformaldehyde (PFA) for 20 min at room temperature and then
incubated with FITC-conjugated wheat germ agglutinin (WGA; Sigma-
Aldrich) and To-Pro nuclear dye (Invitrogen) for 30 min at room
temperature. Three to five washes with phosphate-buffered saline (PBS)
were performed after each step. All images were captured using a Leica SP2
confocal microscope. Ten photographs per muscle section were collected,
and 800 myofibres were measured and analyzed per mouse using ImageJ
software (Schneider et al., 2012) to determine the CSA, minimal Feret
diameter and centralized nuclei count.
For H&E staining, dissected muscles were fixed in Bouin fluid and
embedded in paraffin. Transverse sections (5-8 μm thick) were stained with
H&E according to standard procedure (Slaoui et al., 2017). Images of
stained sections were acquired with an Axiocam camera (Zeiss) at a
magnification of 200×. The number of fibres was determined using ImageJ
software and expressed as a percentage of the total fibre count.
Immunohistochemistry
For immunohistochemistry, 5 μmcryosections ofmouseTAmuscleswere fixed
in 4% PFA in PBS and permeabilized with 0.1% Triton X-100 in PBS.
Nonspecific binding was blocked with 5% bovine serum albumin and 0.1%
Triton X-100 in PBS solution. Sections were stained overnight with rabbit
polyclonal primary antibodies that recognized the C-terminal epitope of
dystrophin (ab15277, 1:250, Abcam), other DAGC components (ab188873,
ab189254, Abcam; sc-14176, Santa Cruz Biotechnology; all 1:500), and Alexa
Fluor 488 goat anti-rabbit secondary antibody (ab150077, 1:1000, Abcam) for
1 h. Nuclei were counterstained with To-Pro dye. Antibodies and To-Pro dye
were diluted in blocking buffer. Three 15 min washes with 0.1% Triton X-100
in PBS were included after each step. Section images were captured on the SP2
Leica microscope or DMI6000 Leica microscope.
Fig. 10. Chromatin interactions in the human
DMD gene. Heat map visualization of Hi-C
interactions in the 1 Mb region of the DMD gene
with 40 kb resolution (data from YUE Lab
interactive Hi-C browser; promoter.bx.psu.edu/
hi-c/view.php/). The black rectangle shows the
location of the deletion. The arrows point to a
spot that indicates an increased number of
contacts between loci homologous to those
flanking the deletion. RefSeq, DNase, CTCF
and Rad21 data are also shown.
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Western blot analysis
For western blot analysis, 100 mg of muscle was collected, physically
disrupted and homogenized with a pestle in the presence of silicon dioxide
powder and 1 ml of lysis buffer [75 mM Tris-HCl (pH 6.8), 10% SDS, 20%
glycerol, 5% mercaptan, 0.001% bromophenol blue] and incubated at 95°C
for 10 min to denature proteins. Each well on a precast mini-protean TGX
4-15% gel (Bio-Rad) was loaded with 5 μg of total protein. Proteins were
transferred onto a nitrocellulose membrane using a standard wet transfer in
Mini Trans-Blot Cell (Bio-Rad) using the manufacturer’s protocol.
Nonspecific binding was blocked by incubating the membranes in 5% dry
milk in PBS for 3 h. Antibodies against target proteins (ab154168 1:1000,
ab15277 1:400, ab188873 1:1000, ab189254 1:1000, ab15200 1:200,
Abcam; NCL-b-DG 1:200, Novocastra; sc-14176 1:200, sc-304 1:200,
Santa Cruz Biotechnology) or a rabbit monoclonal anti-actin antibody
(A2103 1:10,000, Sigma-Aldrich) diluted in 1% dry milk in PBS were used
for protein detection. Incubation with each antibody was carried out
overnight at 4°C, followed by washes and incubation with corresponding
horseradish peroxidase (HRP)-conjugated secondary antibodies (1/3000)
for 1 h at room temperature and further washes in PBS. Enhanced
chemiluminescence was used for the detection of protein bands, and
images were obtained and analyzed on a C-DiGit Blot Scanner.
Creatine phosphate kinase level measurement
Cardiac puncture under avertin anaesthesia was used to collect 250 μl of
blood in an Eppendorf tube before sacrifice. Blood was left for 15 min
at room temperature to promote clot formation before centrifugation (3500 g
for 10 min at 4°C) and serum collection. Serum samples were stored at
−80°C until analysis. CK activity was determined using the Creatine Kinase
Activity Assay Kit (Sigma-Aldrich) and the Synergy 4 instrument (BioTek
Instruments).
Wire hanging test and muscle force examinations
The wire hanging test was performed according to the protocol described
in Aartsma-Rus and van Putten (2014) on 2 mm wire installed 37 cm
above a layer of bedding. We compared the 2-3 month, 4-6 month, 7-9
month and 10-12 month age groups of DMDdel8-34 mice with their age-
matched wild-type littermates. Each mouse was given three trials, and
the maximum hanging time (the longest of the trials) was recorded and used
for analysis.
The protocol for muscle preparation and lengthening was acquired from
previous reports (Chan et al., 2007; Dellorusso et al., 2001) with little
modification. Mice were anaesthetized with an initial intraperitoneal
injection of 50 mg/kg Zoletil 100 (Virbac) and 5 mg/kg Rometar
(Bioveta). The tendon of the TA was exposed by an incision at the ankle.
The tendon was cut several millimetres distal to the end of the muscle and
tied with a 4.0 nylon suture. The tendon and exposed musclewere kept moist
by periodic applications of physiological saline. All experiments were
conducted at room temperature (22-24°C). The foot and ankle of the mouse
were fixed, and the tendon of the muscle was tied securely to the lever arm of
a servomotor. All data were recorded using PowerGraph. The TA muscle
was exposed to two stretches in situ at 100 Hz (frequency resulted in
maximum tetanic force Po). The TA muscle was stimulated with 0.2 ms
pulses via two electrodes that penetrated the skin on either side of the
peroneal nerve near the knee. At the start of the experiment, the muscle was
set to its optimum length (Lo) by finding the length that produced the
maximum twitch force (Pt). Electrical stimulation started at time 0 ms. At
750 ms, the muscle was stretched at 1 mm/s until it was 15% longer than its
optimum length, held at this length for 2 s, and then returned at the same rate
to its original length. Stimulation was stopped at 5000 ms. A second
lengthening contraction identical to the first was administered 10 s later, and
the maximum isometric force was measured after 1 min, 5 min, 10 min and
15 min (P1, P5, P10 and P15, respectively). The maximum isometric force
drop-off at 1 min corresponded to the muscle force deficit after the second
lengthening [(Po-P1)/Po×100%]. The maximum isometric force exchange
at 15 min corresponded to muscle recovery after the second lengthening
[(P15-P1)/Po×100%]. After determination of the muscle’s contractile
properties, the muscle was excised, blotted on filter paper and weighed on
an analytical balance. The total muscle CSA was approximated
mathematically by dividing the muscle mass by the product of optimum
fibre length (Lf) and 1.06 mg/mm3, the density of mammalian muscle. Lf
was determined by multiplying Lo by the previously determined ratio of
muscle length to fibre length (0.6 for TA muscle; Burkholder et al., 1994).
Because absolute Po depends upon muscle size, Po values were normalized
to muscle CSA (Po is divided by the calculated total muscle CSA) and
expressed as the specific force (sPo; kN/mm2), where sPo=Po×(muscle
mass/CSA).
Statistical analysis
Data are mean±2 s.e.m. for normally distributed data. Differences identified
between cohorts were determined using one-way ANOVA with Fisher’s
LSD post hoc test. For non-normally distributed data, the results are
expressed as the median±95% confidence interval. Pairwise comparisons
were performed using theMann–WhitneyU-test for nonparametric data. All
data analyses were performed using SPSS statistics IBM software V.25.
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Meng, G., Müller, C. R., Lindlöf, M., Kaariainen, H. et al. (1989). The molecular
basis for Duchenne versus Becker muscular dystrophy: correlation of severity with
type of deletion. Am. J. Hum. Genet. 45, 498-506.
Korablev, A. N., Serova, I. A. and Serov, O. L. (2017). Generation of megabase-
scale deletions, inversions and duplications involving the Contactin-6 gene in
mice by CRISPR/Cas9 technology. BMC Genet. 18, 112. doi:10.1186/s12863-
017-0582-7
Labun, K., Montague, T. G., Gagnon, J. A., Thyme, S. B. and Valen, E. (2016).
CHOPCHOP v2: a web tool for the next generation of CRISPR genome
engineering. Nucleic Acids Res. 44, W272-W276. doi:10.1093/nar/gkw398
Le Guiner, C., Servais, L., Montus, M., Bodvael, F., Gjata, B., Hogrel, J. Y.,
Carlier, P., Moullec, S., Masurier, C., Adjali, O. et al. (2015). Adeno-associated
virus vector (AAV) microdystrophin gene therapy prolongs survival and restores
muscle function in the canine model of Duchenne muscular dystrophy (DMD).
Neuromuscul. Disord. 25, S315. doi:10.1016/j.nmd.2015.06.458
Le Rumeur, E. (2015). Dystrophin and the two related genetic diseases, Duchenne
and Becker muscular dystrophies. Bosn. J. Basic Med. Sci. 15, 14-20. doi:10.
17305/bjbms.2015.636
Malik, V., Rodino-Klapac, L. R., Viollet, L., Wall, C., King, W., Al-Dahhak, R.,
Lewis, S., Shilling, C. J., Kota, J., Serrano-Munuera, C. et al. (2010).
Gentamicin-induced readthrough of stop codons in Duchenne muscular
dystrophy. Ann. Neurol. 67, 771-780. doi:10.1002/ana.22024
Mcgreevy, J. W., Hakim, C. H., Mcintosh, M. A. and Duan, D. (2015). Animal
models of Duchenne muscular dystrophy: from basic mechanisms to gene
therapy. Dis. Model. Mech. 8, 195-213. doi:10.1242/dmm.018424
Mendell, J. R. and Lloyd-Puryear, M. (2013). Report of MDA muscle disease
symposium on newborn screening for Duchenne muscular dystrophy. Muscle
Nerve 48, 21-26. doi:10.1002/mus.23810
Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M. and Valen, E. (2014).
CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic
Acids Res. 42, W401-W407. doi:10.1093/nar/gku410
Nakamura, A., Fueki, N., Shiba, N., Motoki, H., Miyazaki, D., Nishizawa, H.,
Echigoya, Y., Yokota, T., Aoki, Y. and Takeda, S. (2016). Deletion of exons 3−9
encompassing a mutational hot spot in the DMD gene presents an asymptomatic
phenotype, indicating a target region for multiexon skipping therapy. J. Hum.
Genet. 61, 663-667. doi:10.1038/jhg.2016.28
Niks, E. H. and Aartsma-Rus, A. (2017). Exon skipping: a first in class strategy for
Duchenne muscular dystrophy. Expert Opin Biol. Ther. 17, 225-236. doi:10.1080/
14712598.2017.1271872
Passamano, L., Taglia, A., Palladino, A., Viggiano, E., D’Ambrosio, P.,
Scutifero, M., Rosaria Cecio, M., Torre, V., DE Luca, F., Picillo, E. et al.
(2012). Improvement of survival in Duchenne Muscular Dystrophy: retrospective
analysis of 835 patients. Acta Myol. 31, 121-125.
Sakurai, T., Kamiyoshi, A., Watanabe, S., Sato, M. and Shindo, T. (2008). Rapid
zygosity determination in mice by SYBRGreen real-time genomic PCR of a crude
DNA solution. Transgenic Res. 17, 149-155. doi:10.1007/s11248-007-9134-7
Schneider, C. A., Rasband,W. S. and Eliceiri, K. W. (2012). NIH Image to ImageJ:
25 years of image analysis. Nat. Methods 9, 671-675. doi:10.1038/nmeth.2089
Shen, H., Strunks, G. D., Klemann, B. J., Hooykaas, P. J. and de Pater, S. (2017).
CRISPR/Cas9-induced double-strand break repair in arabidopsis
nonhomologous end-joining mutants. G3 (Bethesda) 7, 193-202. doi:10.1534/
g3.116.035204
Sicinski, P., Geng, Y., Ryder-Cook, A., Barnard, E., Darlison, M. and Barnard, P.
(1989). The molecular basis of muscular dystrophy in the mdx mouse: a point
mutation. Science 244, 1578-1580. doi:10.1126/science.2662404
Slaoui, M., Bauchet, A.-L. and Fiette, L. (2017). Tissue Sampling and Processing
for Histopathology Evaluation. Methods Mol. Biol. 1641, 101-114. doi:10.1007/
978-1-4939-7172-5_4
Toh, Z. Y. C., Thandar Aung-Htut, M., Pinniger, G., Adams, A. M.,
Krishnaswarmy, S., Wong, B. L., Fletcher, S. and Wilton, S. D. (2016).
Deletion of Dystrophin in-frame exon 5 leads to a severe phenotype: guidance for
exon skipping strategies. PLoS ONE 11, e0145620. doi:10.1371/journal.pone.
0145620
Vulin, A., Wein, N., Simmons, T. R., Rutherford, A. M., Findlay, A. R., Yurkoski,
J. A., Kaminoh, Y. and Flanigan, K. M. (2015). The first exon duplication mouse
model of Duchenne muscular dystrophy: a tool for therapeutic development.
Neuromuscular Disord. 25, 827-834. doi:10.1016/j.nmd.2015.08.005
Wang, L., Shao, Y., Guan, Y., Li, L., Wu, L., Chen, F., Liu, M., Chen, H., Ma, Y., Ma,
X. et al. (2015). Large genomic fragment deletion and functional gene cassette
knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos.
Sci. Rep. 5, 17517. doi:10.1038/srep17517
Wells, D. J. (2018). Tracking progress: an update on animal models for Duchenne
muscular dystrophy. Dis. Model. Mech. 11, dmm035774. doi:10.1242/dmm.
035774
White, S. J. and den Dunnen, J. T. (2006). Copy number variation in the genome;
the human DMD gene as an example. Cytogenet Genome Res. 115, 240-246.
doi:10.1159/000095920
Yang, R. C., Yang, S. L., Jin, S. H., Chen, H. W., Jong, Y. J., Chen, S. S. and
Suzuki, Y. (1994). Detection of dystrophin gene deletion in Chinese Duchenne/
Becker muscular dystrophy patients utilizing multiplex polymerase chain reaction.
Gaoxiong Yi Xue Ke Xue Za Zhi 10, 1-8.
Young, C. S. and Pyle, A. D. (2016). Exon skipping therapy. Cell. Elsevier 167,
1144.
Zhang, Y., Mccord, R. P., Ho, Y.-J., Lajoie, B. R., Hildebrand, D. G., Simon, A. C.,
Becker, M. S., Alt, F.W. andDekker, J. (2012). Spatial organization of themouse
genome and its role in recurrent chromosomal translocations. Cell 148, 908-921.
doi:10.1016/j.cell.2012.02.002
Zhang, L., Jia, R., Palange, N. J., Satheka, A. C., Togo, J., An, Y., Humphrey, M.,
Ban, L., Ji, Y., Jin, H. et al. (2015). Large genomic fragment deletions and
insertions in mouse using CRISPR/Cas9. PLoS ONE 10, e0120396. doi:10.1371/
journal.pone.0120396
13
RESOURCE ARTICLE Disease Models & Mechanisms (2019) 12, dmm037655. doi:10.1242/dmm.037655
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
